Welcome to our dedicated page for Avanos Medical SEC filings (Ticker: AVNS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Avanos Medical, Inc. filings document the regulatory record of a medical technology company with product portfolios in Specialty Nutrition Systems and Pain Management and Recovery. Current reports furnish operating results, segment performance, investor presentations, material definitive agreements, executive compensation actions and organizational restructuring disclosures.
Proxy materials describe annual meeting matters, board elections, governance practices and compensation programs. The filings also cover capital-structure disclosures, shareholder voting matters, product-portfolio descriptions for enteral feeding and non-opioid pain therapies, and formal exhibits tied to material events.
Avanos Medical, Inc. executive Kerr W. Holbrook, the SVP and Chief Commercial Officer, reported open-market sales of company common stock. On 11/18/2025, he sold a total of 15,000 shares of Avanos Medical common stock in several transactions at prices ranging from $11.00 to $11.02 per share. After these sales, Holbrook directly beneficially owned 83,860 shares of Avanos Medical common stock.
AVNS filed a Form 144 notice for a proposed sale of 15,000 shares of common stock through Fidelity Brokerage Services LLC on the NYSE, with an aggregate market value of $165,014.21. The shares to be sold were acquired from the issuer between 2023 and 2025 through restricted stock vesting and employee stock purchase plan (ESPP) transactions, including 6,202 shares from restricted stock vesting on 03/04/2025. The table shows 46,418,907 shares of common stock outstanding as a baseline figure. By signing the notice, the seller represents that they are not aware of any undisclosed material adverse information about AVNS’s current or prospective operations.
Armistice Capital, LLC and Steven Boyd filed a Schedule 13G reporting beneficial ownership of 2,500,000 shares of Avanos Medical, Inc. (AVNS) common stock, representing 5.39% of the class. They report shared voting and shared dispositive power over these shares, with no sole voting or dispositive power. The filing cites 46,418,907 shares outstanding as of October 29, 2025 (per the issuer’s 10‑Q).
The filing is certified as acquired and held in the ordinary course of business and not for the purpose of changing or influencing control. The date of the event requiring the filing is September 30, 2025.
Avanos Medical (AVNS) reported Q3 2025 results showing modest top-line growth but weaker profitability. Net sales were $177.8 million versus $170.4 million a year ago, driven by Specialty Nutrition Systems (SNS) at $114.0 million and Pain Management & Recovery (PM&R) at $59.0 million. Gross profit fell to $86.0 million from $92.9 million as cost of products sold increased. Operating income was $0.1 million, and the company posted a net loss of $1.4 million (diluted EPS $(0.03)).
Year to date, net sales reached $520.3 million versus $508.2 million, with an operating loss of $64.1 million reflecting a $77.0 million goodwill impairment in PM&R recorded earlier in 2025. Net loss was $71.6 million (diluted EPS $(1.55)). Cash and cash equivalents were $70.5 million, down from $107.7 million at year-end, after funding investments and debt repayments; the revolver was reduced to $0 and the term loan stood at $103.1 million.
Strategic moves included acquiring Nexus Medical for $27.0 million in cash (up to $20.0 million contingent). The deal added $0.9 million of net sales since closing and brought $20.5 million of identifiable intangibles and $14.0 million of goodwill. Restructuring continued, with $10.3 million in Q3 costs; management expects up to $10.0 million additional expenses and annualized savings of $15.0–$20.0 million as initiatives extend through 2026.
Avanos Medical, Inc. filed an 8-K to announce results for the three and nine months ended September 30, 2025. The company reported its results of operations and financial condition for these periods.
The announcement was provided via a press release furnished as Exhibit 99.1. The company stated the information under Item 2.02, including Exhibit 99.1, is being furnished and not deemed filed under the Exchange Act.
The Vanguard Group filed Amendment No. 12 to Schedule 13G on Avanos Medical (AVNS), reporting beneficial ownership of 3,425,214 shares of common stock, representing 7.38% of the class as of 09/30/2025. Vanguard reports 0 shares with sole voting power and 371,596 with shared voting power. It has 2,979,548 shares with sole dispositive power and 445,666 with shared dispositive power.
Vanguard is identified as an investment adviser and certifies the holdings were acquired and are held in the ordinary course of business and not to change or influence control. Dividends and sale proceeds are for Vanguard’s clients, including registered investment companies and other managed accounts, with no single client over 5%.
Avanos Medical (AVNS) is eliminating its Chief Commercial Officer and General Counsel positions as part of a broader restructuring, effective December 1, 2025. The company notified Senior Vice Presidents Kerr Holbrook (CCO) and Mojirade James (General Counsel and Secretary) of their employment termination tied to the role eliminations, with responsibilities to be reallocated across other employees.
Under the Severance Pay Plan, Avanos will pay $1,535,417 to Mr. Holbrook and $1,425,665 to Ms. James, and cover 100% of COBRA premiums for 12 months. Unvested time-based RSUs will vest pro rata through the termination date, PSUs will vest at period end based on actual performance, and stock options will remain exercisable for five years (or earlier expiration). Each executive will receive a prorated 2025 bonus at target. These benefits are conditioned on signed separation agreements, a general release, and continued compliance with confidentiality and non-solicitation obligations.
Dimensional Fund Advisors LP reports ownership of 2,352,634 shares of Avanos Medical Inc common stock, representing 5.1% of the outstanding class. The filing shows Dimensional has sole voting power over 2,282,916 shares and sole dispositive power over 2,352,634 shares, while disclaiming beneficial ownership because the shares are owned by client Funds. The statement clarifies these holdings are managed in an advisory capacity for multiple commingled funds and separate accounts and are held in the ordinary course of business without intent to influence control.
T. Rowe Price Investment Management, Inc. filed a Schedule 13G/A disclosing beneficial ownership of 4,713,494 shares of Avanos Medical, Inc. common stock, representing 10.2% of the class as of 09/30/2025. The filer reports sole voting power for 4,683,148 shares and sole dispositive power for 4,713,494 shares. The filing notes that T. Rowe Price Small-Cap Value Fund holds 2,546,726 shares (about 5.5%) as part of its managed portfolio. The statement affirms the securities are held in the ordinary course of business and not for the purpose of changing control.
Avanos Medical, Inc. reported that on September 15, 2025 it acquired Nexus Medical, LLC. The company disclosed this event through a current report and referenced a press release that provides more information about the transaction.
The press release announcing the acquisition is attached as Exhibit 99.1 and is furnished under Regulation FD, meaning it is intended to share information broadly with the market but is not treated as filed for liability purposes under certain securities laws. Avanos’ common stock continues to trade on the New York Stock Exchange under the symbol AVNS.
Avanos Medical, Inc. reported that on September 15, 2025 it acquired Nexus Medical, LLC. The company disclosed this event through a current report and referenced a press release that provides more information about the transaction.
The press release announcing the acquisition is attached as Exhibit 99.1 and is furnished under Regulation FD, meaning it is intended to share information broadly with the market but is not treated as filed for liability purposes under certain securities laws. Avanos’ common stock continues to trade on the New York Stock Exchange under the symbol AVNS.